Abstract
Currently approved HER2-targeting antibody-drug conjugates (ADCs) for HER2-positive breast cancer (BC) are associated with safety concerns. In this multicenter, single-arm, dose-escalation (phase 1a) and dose-expansion (phase 1b) phase 1 trial (NCT03944499), patients with HER2-expressing advanced solid tumors received FS-1502 (an anti-HER2 ADC) with a 3 + 3 design in phase 1a; patients with metastatic HER2-positive BC received FS-1502 at the recommended phase 2 dose (RP2D) in phase 1b. The primary end points were dose-limiting toxicities (DLTs), maximum tolerated dose (MTD) and RP2D for phase 1a and objective response rate (ORR) for phase 1b. A total of 150 patients with HER2-expressing solid tumors (n = 5) and BC (n = 145) were enrolled (female, n = 146, 97.3%). One DLT each was reported at 3.0 and 3.5 mg/kg; the MTD was not reached. The RP2D was 2.3 mg/kg once every 3 weeks. Five (3.3%) patients experienced pneumonitis; four (2.7%) had grade 3 reversible ocular events. Of 67 HER2-positive BC patients receiving the RP2D, the best ORR was 53.7% (95% CI, 41.1-66.0%), including PRs confirmed (confirmed ORR, 37.5%) and pending for confirmation. FS-1502 was well tolerated with limited ocular and pulmonary findings and demonstrated promising antitumor activity in HER2-positive BC patients.
Introduction
The advent of HER2-targeting antibody-drug conjugates (ADCs) like trastuzumab deruxtecan (T-DXd) and trastuzumab emtansine (T-DM1) has significantly improved outcomes for patients with HER2-positive metastatic breast cancer (mBC). However, these agents are often associated with serious toxicities, such as interstitial lung disease (ILD)/pneumonitis, ocular issues, and gastrointestinal distress. Furthermore, resistance eventually limits their long-term efficacy. There is a clear clinical need for next-generation ADCs that utilize improved linker technologies and payloads to enhance the therapeutic window—maximizing tumor-killing efficacy while minimizing off-target damage to healthy tissues.
Methods
This multicenter, open-label Phase 1 trial evaluated FS-1502, a novel HER2-targeting ADC. FS-1502 is engineered with site-specific chemoenzymatic conjugation to ensure a homogeneous drug-to-antibody ratio (DAR). It features a cleavable $\beta$-glucuronide linker, designed to remain stable in systemic circulation but undergo rapid enzymatic cleavage by $\beta$-glucuronidase, which is highly expressed in the tumor microenvironment. The payload is monomethyl auristatin F (MMAF), a potent antimitotic agent.
Study Design
The trial was divided into two phases:
- Phase 1a (Dose Escalation): Used a "3 + 3" design to evaluate safety across doses ranging from 0.1 mg/kg to 3.5 mg/kg, aiming to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D).
- Phase 1b (Dose Expansion): Assessed the efficacy and safety of the RP2D in a larger cohort of patients with HER2-positive mBC.
Patient Population
A total of 150 patients were enrolled (145 with breast cancer, 5 with other HER2-expressing solid tumors). The population was heavily pre-treated, with 88.7% of patients having received a median of three prior lines of therapy, including trastuzumab and pyrotinib.
Results
Safety and Tolerability
The MTD was not reached, and the RP2D was established at 2.3 mg/kg administered once every three weeks (Q3W). FS-1502 demonstrated a manageable safety profile. Notably, the incidence of severe pulmonary and ocular toxicities was low: only 3.3% of patients experienced pneumonitis, and grade 3 ocular events occurred in only 2.7% of patients and were reversible. Pharmacokinetic data indicated that the site-specific conjugation and stable linker resulted in very low levels of free-circulating MMAF, which likely accounts for the reduced systemic side effects.
Antitumor Activity
Among the 67 patients with HER2-positive mBC treated at the RP2D, FS-1502 showed robust antitumor activity. The best objective response rate (ORR) was 53.7% (confirmed ORR: 37.5%), and the disease control rate (DCR) was 88.1%. The median progression-free survival (PFS) was 15.5 months.
Activity was also noted in patients with HER2-low expression (ORR 26.7%), suggesting that FS-1502 may have utility beyond the strictly HER2-positive population.
Discussion and Conclusion
FS-1502 demonstrates promising efficacy and a differentiated safety profile in heavily pre-treated HER2-positive mBC. Its unique site-specific conjugation and $\beta$-glucuronide linker technology appear to mitigate some of the "Achilles' heels" of earlier ADCs, particularly regarding pulmonary and ocular toxicities. While these Phase 1 results are encouraging, the single-arm design and small subgroup sizes necessitate further validation. A randomized Phase 3 trial is currently underway comparing FS-1502 directly against T-DM1 to definitively establish its place in the treatment paradigm.
Summary updated